DK3448364T3 - Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose - Google Patents

Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose Download PDF

Info

Publication number
DK3448364T3
DK3448364T3 DK17790646.8T DK17790646T DK3448364T3 DK 3448364 T3 DK3448364 T3 DK 3448364T3 DK 17790646 T DK17790646 T DK 17790646T DK 3448364 T3 DK3448364 T3 DK 3448364T3
Authority
DK
Denmark
Prior art keywords
macrophages
atherosclerosis
targeting
dissolve
accumulation
Prior art date
Application number
DK17790646.8T
Other languages
English (en)
Inventor
Willem Mulder
Zahi Fayad
Francois Fay
Jordi Ochando
Mounia Braza
Raphael Duivenvoorden
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK3448364T3 publication Critical patent/DK3448364T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1224Lipoprotein vesicles, e.g. HDL and LDL proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1275Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK17790646.8T 2016-04-29 2017-05-01 Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose DK3448364T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662329676P 2016-04-29 2016-04-29
PCT/US2017/030444 WO2017190145A1 (en) 2016-04-29 2017-05-01 Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Publications (1)

Publication Number Publication Date
DK3448364T3 true DK3448364T3 (da) 2022-05-02

Family

ID=60161161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17790646.8T DK3448364T3 (da) 2016-04-29 2017-05-01 Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose

Country Status (11)

Country Link
US (2) US20190290593A1 (da)
EP (2) EP3448364B1 (da)
JP (2) JP7262100B2 (da)
CN (2) CN116077439A (da)
AU (2) AU2017257189B2 (da)
CA (1) CA3021645A1 (da)
DK (1) DK3448364T3 (da)
ES (1) ES2913073T3 (da)
PL (1) PL3448364T3 (da)
PT (1) PT3448364T (da)
WO (1) WO2017190145A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218619A (zh) * 2017-11-20 2021-01-12 西奈山伊坎医学院 通过治疗性纳米生物制剂组合物抑制驯化免疫
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2021102433A1 (en) * 2019-11-22 2021-05-27 The Research Foundation For The State University Of New York Compositions and methods for use in type 1 diabetes
CN111494320A (zh) * 2020-04-24 2020-08-07 上海交通大学医学院附属仁济医院 一种载糖皮质激素的纳米载体及其制备和应用
CN117355298A (zh) * 2021-03-19 2024-01-05 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
CN114788835B (zh) * 2022-04-07 2024-01-23 中山大学附属第三医院 Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
CA2517675A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
EP2134740A2 (en) 2007-04-09 2009-12-23 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
WO2010047839A1 (en) 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
KR101253399B1 (ko) * 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
WO2013192310A1 (en) * 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
EP2703384A1 (en) 2012-08-27 2014-03-05 Ludwig-Maximilians-Universität München Inhibitors of CD40-TRAF6 interaction
WO2016019333A1 (en) * 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US20200281962A1 (en) * 2015-12-18 2020-09-10 Northwestern University Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps)

Also Published As

Publication number Publication date
JP2019515926A (ja) 2019-06-13
US20230218537A1 (en) 2023-07-13
PT3448364T (pt) 2022-05-04
WO2017190145A1 (en) 2017-11-02
PL3448364T3 (pl) 2022-08-16
EP3448364A1 (en) 2019-03-06
CN109640959A (zh) 2019-04-16
AU2017257189A1 (en) 2018-11-15
JP2023085437A (ja) 2023-06-20
JP7262100B2 (ja) 2023-04-21
AU2022204675A1 (en) 2022-09-15
EP3448364A4 (en) 2019-12-25
US20190290593A1 (en) 2019-09-26
EP4014967A1 (en) 2022-06-22
CA3021645A1 (en) 2017-11-02
ES2913073T3 (es) 2022-05-31
CN116077439A (zh) 2023-05-09
CN109640959B (zh) 2023-03-17
AU2017257189B2 (en) 2022-03-31
EP3448364B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
DK3448364T3 (da) Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose
GB201906670D0 (en) Systems and methods to detect stress allergy and thermal asymmetry
DK3349351T3 (da) Integreret apparat og system til udnyttelse af solenergi
DK3560098T3 (da) Fotovoltaik-anlæg og tilhørende anvendelse
DK3285055T3 (da) Magnetostriktive sensorer uden kontakt og fremgangsmåder til anvendelse af sensorerne
MA49715A (fr) Oligomères et conjugués d'oligomères
DK2909808T3 (da) Forbedringer i og i forbindelse med behandling af undersøgelsesdata om en undervandsscene
DK2971167T3 (da) Sammensætninger og fremgangsmåder til targeting af nucleinsyre med nucleinsyrer
DK2949924T3 (da) Systemer og fremgangsmåder til omkalibrering af vindmøllenacelleposition og vindretningsestimering
DK3174976T3 (da) Fremgangsmåder og systemer til forarbejdning af partikler
DK2965479T3 (da) Fremgangsmåder og systemer til forbedret detektering af e-navigationsmeddelelser
DK3034868T3 (da) Systemer og metoder til øgning af vindturbinekraftoutput
DK3409083T3 (da) Forbedringer af og i forbindelse med datacentre
DK3067575T3 (da) Skrue til undgåelse af revner og grater
DK3087761T3 (da) Høreapparat som kan indsættes i øregangen og høreapparatsystem
DK3380313T3 (da) Forbedringer vedrørende fremstillingen af vindmøllevinger
DK3104717T3 (da) Saccharosereduktion og generering af uopløselige fibre i juice
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3619362T3 (da) Forbedringer af og i forbindelse med barrierer
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
DK2962113T3 (da) Systemer og fremgangsmåder med anti-p40-antistoffer
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3394778T3 (da) Fremgangsmåde og system til at forbedre sikkerheden af en transaktion
DK3188051T3 (da) Systemer og fremgangsmåder til generering af søgeskabeloner
DK3163069T3 (da) Vindturbine-montagesystem og tilhørende fremgangsmåde